DEA Backs Cannabis Schedule III Move at Administrative Hearing
Federal agency signals support for rescheduling with limited witness testimony as industry awaits regulatory shift that could reshape taxation and banking.
The Drug Enforcement Administration opened its administrative hearing this week by declaring support for rescheduling cannabis from Schedule I to Schedule III, marking a pivotal moment in federal cannabis policy. DEA attorney James Schwartz informed the tribunal that the government plans to call just two witnesses—a scientist and a medical expert—to support the rescheduling proposal, suggesting confidence in the agency's position.
The streamlined witness list indicates the DEA views the scientific and medical evidence as overwhelmingly favorable for rescheduling. This administrative hearing represents the final procedural step before the agency can implement the policy change recommended by the Department of Health and Human Services last year. The hearing process typically allows for public comment and expert testimony from multiple stakeholders.
Rescheduling cannabis to Schedule III would eliminate the punitive 280E tax provision that prevents cannabis companies from deducting standard business expenses. This change could dramatically improve profit margins across the industry, with some analysts projecting 20-30% increases in net income for major operators. Multi-state operators like Curaleaf, Green Thumb Industries, and Trulieve stand to benefit most significantly given their substantial federal tax burdens.
The regulatory shift would also facilitate banking relationships and potentially accelerate institutional investment in cannabis stocks. While Schedule III classification maintains federal prohibition for recreational use, it acknowledges accepted medical applications and lower abuse potential compared to Schedule I substances like heroin and LSD.
The hearing's outcome could materialize within months, creating a catalyst for cannabis equity valuations that have languished due to regulatory uncertainty. The DEA's public support removes a major hurdle, though final implementation still requires navigating federal rulemaking procedures and potential legal challenges from prohibition advocates.